Oral Mucosal Effects In Adult Smokers Associated With Two Nicotine Lozenge Formulations

NCT ID: NCT03087786

Last Updated: 2021-01-11

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-21

Study Completion Date

2017-08-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To study the oral mucosal effects in adult smokers associated with the use of two Nicotine Lozenge formulations.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To assess the oral mucosal health associated with 3 weeks of use of test product, Nicotine Bitartrate 4 mg mint lozenge, relative to a reference product, Nicorette® \[Nicotine Polacrilex\] 4 mg mint lozenge, in healthy adult smokers motivated to quit smoking.

To evaluate the safety and tolerability of Nicotine Bitartrate 4 mg mint lozenge and Nicorette® \[Nicotine Polacrilex\] 4 mg mint lozenge in this subject population.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Safety Issues

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nicotine Bitartrate 4mg Lozenge

Nicotine Bitartrate Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days

Group Type EXPERIMENTAL

Nicotine Bitartrate Lozenge 4mg

Intervention Type DRUG

Test Product

Nicotine Polacrilex 4mg Lozenge

Nicotine Polacrilex Lozenge 4mg. Take 1 lozenge every 1-2 hours, as needed for 21 days

Group Type ACTIVE_COMPARATOR

Nicotine Polacrilex 4Mg Lozenge

Intervention Type DRUG

Active Comparator

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nicotine Bitartrate Lozenge 4mg

Test Product

Intervention Type DRUG

Nicotine Polacrilex 4Mg Lozenge

Active Comparator

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Test Product Nicorette Lozenge 4mg

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Potential subjects who meet the following criteria at Screening may be included in the study.

1. Sex and Age: Males and females aged at least 18 years and older.
2. Informed of the nature of the study and have agreed to and are able to read, review, and sign the informed consent document prior to commencing any study specific procedures. The informed consent document will be written in English, therefore the volunteer must have the ability to read and communicate in English.
3. Must have smoked at least 10 cigarettes per day for the previous 12 months prior to screening.
4. Must smoke first cigarette within 30 minutes of waking up.
5. Must be motivated to quit smoking upon enrollment into the study.
6. Contraception: Females of childbearing potential who have been, in the opinion of the Investigator, practicing a reliable method of contraception for at least two months prior to study participation and must agree to remain on an acceptable method of contraception while participating in the study period using the study medication. Acceptable methods of contraception are hormonal birth control, intrauterine device, double barrier methods, vasectomized partner or abstinence.
7. Females of childbearing potential will be required to undergo a serum (Screening) and urine (Day 0) pregnancy test (must be negative).
8. Females of non-childbearing potential must be surgically sterile for at least three months prior to Screening or post-menopausal for at least two years.
9. General health: All study participants must have good general health and no impairment that would impede or affect ability to participate in the study as deemed acceptable by the Investigator.
10. Compliance: All study participants must understand and be willing to comply with all study procedures and restrictions.
11. Consent: All study participants must demonstrate willingness to participate as evidenced by voluntary written informed consent and must have received a signed and dated copy of the informed consent form.

Exclusion Criteria

1. Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to become pregnant during the course of the study.
2. Nicotine use:

1. Is unable/unwilling to stop using forms of tobacco (e.g., traditional cigarettes, chewing tobacco, nicotine gels, cigars, snuff tobacco, nicotine patch and electronic cigarettes) for the duration of the study.
2. Is unable/unwilling to stop using other nicotine replacement therapy products throughout the duration of the study.
3. Disease: Has a medical history, which in the opinion of the investigator, would jeopardize the safety of the subject or impact the validity of the study results, e.g., known history of heart disease, recent myocardial infarction or cerebrovascular accident (i.e., within 12 weeks prior to enrollment), unstable angina, severe cardiac arrhythmia, diabetes or peptic ulcer.
4. Demonstrates a reactive screen for Hepatitis B surface antigens, hepatitis C antibody, or HIV antibody.
5. Oral condition:

1. Has history of oral surgery (including extractions) within four weeks of screening, operative dental work within seven days of screening, or a presence of any clinically significant oral pathology (as determined by an oral health professional - dentist or dental hygienist) including lesions, sores or inflammation of the mouth which would interfere with study assessments or confound the results.
2. Has fixed retainers, orthodontic appliances, or either maxillary and/or mandibular dentures or other appliances which may interfere with the placement of the product.
3. Has current or recurrent disease that could affect the site of application, the action, absorption of the study treatment, or clinical assessment.
4. Has severe gingivitis, periodontitis or rampant caries (extensive dental decay, i.e., big/deep cavities, in many teeth), as diagnosed by an oral health professional- dentist or dental hygienist.
5. Has the presence of oral or peri-oral ulceration including herpetic lesions at screening (subjects with these lesions may be re-examined at a subsequent appointment and may be able to be admitted at a later date if the ulceration or herpetic lesion heals) or Study Visit Day 0.
6. Has elective dentistry scheduled during the study duration.
6. Allergy/Intolerance:

1. Has a known or suspected intolerance or hypersensitivity to the study materials (or closely-related compounds) or any of their stated ingredients.
2. Has a known genetic deficiency with an inability to metabolize aspartame or phenylalanine or has been diagnosed with phenylketonuria.
7. Clinical Study Participation:

1. Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit at the start of the study.
2. Previous participation in this study.
8. Substance abuse:

1. Current or recent (within two years of screening) history of drug or alcohol abuse, misuse, physical or psychological dependence.
2. Demonstrates a positive alcohol breath test.
3. Demonstrates a positive urine drug screen without disclosure of corresponding prescribed concomitant medication(s) at Screening and Study Visit Day 0.
9. Urine glucose:

a) Positive glucose urine screen.
10. Personnel:

1. Is an employee of the Sponsor or the study site.
2. Is a member of the same household as another subject in this trial.
11. Use of all over the counter (OTC) and prescription (Rx) lozenges after starting the study (Day 0 and onward).
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Inflamax Research Incorporated

INDUSTRY

Sponsor Role collaborator

Niconovum USA

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Frank Lee, MD, CPI

Role: PRINCIPAL_INVESTIGATOR

Inflamax Research Incorporated

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Inflamax Research Inc

Newark, New Jersey, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Provided Documents

Download supplemental materials such as informed consent forms, study protocols, or participant manuals.

Document Type: Statistical Analysis Plan

View Document

Document Type: Study Protocol

View Document

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2016-NBTL-S-005

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Nicotine Mouth Film for Craving Relief.
NCT01702532 COMPLETED PHASE3
Nicotine Lozenge Bioequivalence Study
NCT01536704 COMPLETED PHASE1
Provoked Craving Relief Study by NRT
NCT01476202 COMPLETED PHASE2